Together, these findings demonstrate that KSR1 can drive RAS/MAPK pathway activation in the liver independently of upstream RAS or RAF mutations, highlighting KSR1 as a promising therapeutic target in HCC with aberrant activation of RAS/MAPK signaling (Figure 6). This evidence concerns the gene RAF1 and hepatocellular carcinoma.